A unique RNA-directed nucleoside analog is cytotoxic to breast cancer cells and depletes cyclin E levels.

abstract：PURPOSE:The results of studies comparing survival in familial and sporadic breast cancer (BC) are inconsistent. A higher incidence of contralateral breast cancer (CBC) has been reported in familial BC. Ascertainment bias may influence both the reported familial CBC and survival. DESIGN:We assessed CBC incidence, dista...

journal_title：Breast cancer research and treatment

authors： Tilanus-Linthorst MM,Bartels KC,Alves C,Bakri B,Crepin E,van den Ouweland A,Klijn JG,Meijers-Heijboer H,Brekelmans CT

更新日期：2006-01-01 00:00:00

abstract：:MCF-7 cells, a metastatic human breast carcinoma line, caused dose-dependent platelet aggregation in heparinized human platelet-rich plasma (PRP). MCF-7 tumor cell-induced platelet aggregation (TCIPA) was almost blocked by apyrase (0.5 U/ml) and completely inhibited by hirudin (5 U/ml). This TCIPA was unaffected by cy...

journal_title：Breast cancer research and treatment

authors： Chiang HS,Swaim MW,Huang TF

更新日期：1995-03-01 00:00:00

abstract：BACKGROUND:Paget's disease of the breast is an uncommon presentation of breast malignancy, accounting for 1-3% of all the breast tumors and presents in different histopathologic patterns: in association with an underlying invasive or non invasive carcinoma, or without any underlying neoplasia. In the literature, differ...

journal_title：Breast cancer research and treatment

authors： Caliskan M,Gatti G,Sosnovskikh I,Rotmensz N,Botteri E,Musmeci S,Rosali dos Santos G,Viale G,Luini A

更新日期：2008-12-01 00:00:00

abstract：:The uptake and retention of a radiolabeled synthetic progestin ORG 2058 by the mammary glands were examined in the baboon. Four estrogen-primed baboons were injected intravenously with 2.5 micrograms/kg body weight of 3H-ORG 2058. One animal received an additional injection of 2.5 mg/kg body weight of unlabeled proges...

journal_title：Breast cancer research and treatment

authors： Weaker FJ,Sheridan PJ

更新日期：1984-01-01 00:00:00

abstract：PURPOSE:The epithelial-mesenchymal transition (EMT) plays a key role in breast cancer progression and metastasis. Lipocalin 2 (LCN2) is involved in the regulation of EMT. The aim of this study was to investigate the clinicopathological significance of LCN2 expression in breast cancer. METHODS:The expression of LCN2 pr...

journal_title：Breast cancer research and treatment

authors： Kurozumi S,Alsaeed S,Orah N,Miligy IM,Joseph C,Aljohani A,Toss MS,Fujii T,Shirabe K,Green AR,Aleskandarany MA,Rakha EA

更新日期：2020-02-01 00:00:00

abstract：PURPOSE:Suberoylanilide hydroxamic acid (SAHA; vorinostat), a small molecule inhibitor of histone deacetylase, attenuates signaling pathways known to confer trastuzumab resistance. A combination of SAHA and trastuzumab may be a promising strategy to improve the efficacy of trastuzumab against breast cancer. In this Pha...

journal_title：Breast cancer research and treatment

authors： Goldstein LJ,Zhao F,Wang M,Swaby RF,Sparano JA,Meropol NJ,Bhalla KN,Pellegrino CM,Katherine Alpaugh R,Falkson CI,Klein P,Sledge GW

更新日期：2017-09-01 00:00:00

abstract：PURPOSE:To investigate the activity of the combination of gemcitabine (G) plus epirubicin (E) and taxol (T), (GET), in metastatic breast cancer, to evaluate the feasibility of this regimen as induction before high dose chemotherapy and to study the pharmacokinetic interactions of these three drugs. PATIENTS AND METHOD...

journal_title：Breast cancer research and treatment

authors： Conte PF,Gennari A,Donati S,Salvadori B,Baldini E,Bengala C,Pazzagli I,Orlandini C,Danesi R,Fogli S,Del Tacca M

更新日期：2001-07-01 00:00:00

abstract：:Psoriasin (S100A7) is a calcium-binding protein that has shown to be highly expressed in high-grade ductal carcinoma in situ (DCIS) and a subset of invasive breast cancers. However, its role in invasion and metastasis is not very well known. In this study, we have shown that S100A7 differentially regulates epidermal g...

journal_title：Breast cancer research and treatment

authors： Sneh A,Deol YS,Ganju A,Shilo K,Rosol TJ,Nasser MW,Ganju RK

更新日期：2013-04-01 00:00:00

abstract：:We have examined a family with a germline BRCA2 mutation in three cases of invasive breast cancer and one case of ductal carcinoma in situ (DCIS). Loss of heterozygosity (LOH) has been demonstrated at the BRCA2 locus in all cases. This result may suggest that the germline mutation in BRCA2 is the initiating step of DC...

journal_title：Breast cancer research and treatment

authors： Thomassen M,Kruse TA,Olsen KE,Borg A,Gerdes AM

更新日期：2004-10-01 00:00:00

abstract：BACKGROUND:Several randomized controlled trials have confirmed the usefulness of trastuzumab as an adjuvant therapy for HER2-overexpressed breast cancer patients; however, the costs for 1-year treatment are high. Therefore, we performed an economic analysis regarding the efficient distribution of medical resources. ME...

journal_title：Breast cancer research and treatment

authors： Shiroiwa T,Fukuda T,Shimozuma K,Ohashi Y,Tsutani K

更新日期：2008-06-01 00:00:00

abstract：PURPOSE:To evaluate factors associated with compliance to the National Comprehensive Cancer Network (NCCN) guidelines for BRCA1/2 testing and identify groups who are at risk of under- and over-use of BRCA1/2 testing. METHODS:Data included 20,758 women from Dr. Susan Love Research Foundation's The Health of Women (HOW)...

journal_title：Breast cancer research and treatment

authors： Silver MI,Klein W,Samimi G,Minasian L,Loud J,Roberts MC

更新日期：2019-02-01 00:00:00

abstract：PURPOSE:Genomic studies have revealed that genomic aberrations play important roles in the progression of this disease. The aim of this study was to evaluate the associations between clinical survival outcomes of the clonality and subclonality status of driver genes in breast cancer. METHODS:We performed an integrated...

journal_title：Breast cancer research and treatment

authors： Lan Y,Zhao E,Luo S,Xiao Y,Li X,Cheng S

更新日期：2019-05-01 00:00:00

abstract：:IBEP-2, an established cell line recently derived from breast carcinoma, was characterized with regard to estrogen receptor (ER) expression, cell mitogenic response to estrogenic stimulation and sensitivity to antiestrogens. In addition, we examined ER modulation following binding of agonist and antagonists, and the E...

journal_title：Breast cancer research and treatment

authors： Journé F,Body JJ,Leclercq G,Nonclercq D,Laurent G

更新日期：2004-07-01 00:00:00

abstract：BACKGROUND:Differences in de novo (dnMBC) and recurrent metastatic breast cancer (rMBC) presentation and survival over time have not been adequately described. METHODS:A retrospective cohort study, 1990-2010, with follow up through 2015 of dnMBC patients (stage IV at diagnosis) and rMBC patients with subsequent distan...

journal_title：Breast cancer research and treatment

authors： Malmgren JA,Mayer M,Atwood MK,Kaplan HG

更新日期：2018-01-01 00:00:00

abstract：:The third category for extent of involution in Table 4 was published incorrectly in the original publication. The correct classification is ≥ 75% and the corrected Table 4 is given in the Correction article. ...

journal_title：Breast cancer research and treatment

authors： Arthur R,Wang Y,Ye K,Glass AG,Ginsberg M,Loudig O,Rohan T

更新日期：2018-07-01 00:00:00

abstract：:This retrospective study investigates the correlation of intra-individual HER2 status between primary breast cancers and corresponding recurrences in a population derived cohort. The REMARK criteria were used as reference. In 151 breast cancer patients, primary tumors were analyzed for HER2 status on histopathology se...

journal_title：Breast cancer research and treatment

authors： Wilking U,Karlsson E,Skoog L,Hatschek T,Lidbrink E,Elmberger G,Johansson H,Lindström L,Bergh J

更新日期：2011-01-01 00:00:00

abstract：PURPOSE:To examine the outcomes of endocrine naive patients treated with tamoxifen as initial endocrine therapy for metastatic breast cancer. Data were obtained from the long-term follow-up of two previously published randomized trials. PATIENTS AND METHODS:All patients received tamoxifen 20 mg po in a single daily do...

journal_title：Breast cancer research and treatment

authors： Kuss JT,Muss HB,Hoen H,Case LD

更新日期：1997-02-01 00:00:00

abstract：PURPOSE:miRNAs have been linked to chemosensitivity of breast cancer cells in vitro. In patients, however, there is no clinically validated method for predicting chemotherapy response. The aim of this study was to assess whether (I) a specific pattern of miRNA expression in pretherapeutic biopsies can predict response ...

journal_title：Breast cancer research and treatment

authors： Raychaudhuri M,Bronger H,Buchner T,Kiechle M,Weichert W,Avril S

更新日期：2017-04-01 00:00:00

abstract：PURPOSE:Radiotherapy (RT) constitutes an important part of breast cancer treatment. However, triple negative breast cancers (TNBC) exhibit remarkable resistance to most therapies, including RT. Developing new ways to radiosensitize TNBC cells could result in improved patient outcomes. The M2 isoform of pyruvate kinase ...

journal_title：Breast cancer research and treatment

authors： Zhang L,Bailleul J,Yazal T,Dong K,Sung D,Dao A,Gosa L,Nathanson D,Bhat K,Duhachek-Muggy S,Alli C,Dratver MB,Pajonk F,Vlashi E

更新日期：2019-11-01 00:00:00

abstract：:Goserelin ('Zoladex'), a luteinizing hormone-releasing hormone (LHRH) agonist induces reversible ovarian ablation in premenopausal women. It is the most extensively studied LHRH agonist for the treatment of breast cancer and data from a large clinical trial program show that, alone or in combination with tamoxifen, go...

journal_title：Breast cancer research and treatment

authors： Jonat W

更新日期：2002-10-01 00:00:00

abstract：:The pharmacokinetics of free and different liposomal formulations of hexadecylphosphocholine (HPC) was investigated in tumor-bearing (human mammary tumor MaTu) and tumor-free mice after intravenous and intraperitoneal administration. The levels of HPC were evaluated at different times in serum, normal tissues, and tum...

journal_title：Breast cancer research and treatment

authors： Arndt D,Zeisig R,Fichtner I,Teppke AD,Fahr A

更新日期：1999-11-01 00:00:00

abstract：:Indole-3-carbinol (I3C) is a promising phytochemical agent in chemoprevention of breast cancer. Our present study is the first description of I3C that significantly inhibits the cell adhesion, spreading and invasion associated with an up-regulation of PTEN (a tumor suppressor gene) and E-cadherin (a regulator of cell-...

journal_title：Breast cancer research and treatment

authors： Meng Q,Goldberg ID,Rosen EM,Fan S

更新日期：2000-09-01 00:00:00

abstract：PURPOSE:Breast tumors from young women under the age of 40 account for approximately 7% of cases and have a poor prognosis independent of established prognostic factors. We evaluated the patient population served by the Military Health System, where a disproportionate number of breast cancer cases in young women are se...

journal_title：Breast cancer research and treatment

authors： Zimmer AS,Zhu K,Steeg PS,Wu A,Gatti-Mays ME,Soltani S,Perkins JG,Shao S,Brown D,Georg M,Hu H,Shriver CD,Lipkowitz S

更新日期：2018-04-01 00:00:00

abstract：:Introduction Trastuzumab is a highly effective therapy for the treatment of HER-2/neu positive breast cancer. To maximize benefit and minimize unnecessary toxicity, patient selection is essential. Currently HER-2/neu analysis is routinely performed only for primary invasive breast cancers, and trastuzumab therapy is r...

journal_title：Breast cancer research and treatment

authors： Lower EE,Glass E,Blau R,Harman S

更新日期：2009-01-01 00:00:00

abstract：:Tumor necrosis factor-α (TNF-α) is an important pro-inflammatory cytokine in the development and progress in human cancer. TNF-α polymorphisms have been confirmed to influence the risk for several types of cancer, however, the associations between TNF-α polymorphisms and breast cancer (BC) remain controversial and amb...

journal_title：Breast cancer research and treatment

authors： Yang Y,Feng R,Bi S,Xu Y

更新日期：2011-09-01 00:00:00

abstract：PURPOSE:To report Chinese women's preferred and perceived participation in breast cancer treatment decision making (TDM), describe influences on women's participation preference and participation congruence (PC) (correspondence between preferred and actual amount of participation in TDM), and explore subsequent satisfa...

journal_title：Breast cancer research and treatment

authors： Lam W,Fielding R,Chan M,Chow L,Ho E

更新日期：2003-07-01 00:00:00

abstract：:The clinicopathologic, mammographic, and sonographic findings in patients with pure ductal carcinoma in situ (DCIS) were assessed by estrogen receptor (ER) expression. After institutional review board approval, patients with pure DCIS evaluated from January 1996 to July 2009 with known ER status and available imaging ...

journal_title：Breast cancer research and treatment

authors： Rauch GM,Kuerer HM,Scoggins ME,Fox PS,Benveniste AP,Park YM,Lari SA,Hobbs BP,Adrada BE,Krishnamurthy S,Yang WT

更新日期：2013-06-01 00:00:00

abstract：:A novel human mammary epithelial cell line, HME348, was established from benign breast tissue from a 44-year-old germ-line BRCA2 mutation carrier with a history of stage 1 breast cancer. Mutation analysis showed that the patient had a known 6872del4 BRCA2 heterozygous mutation. The human mammary epithelial cells passa...

journal_title：Breast cancer research and treatment

authors： Lewis CM,Herbert BS,Bu D,Halloway S,Beck A,Shadeo A,Zhang C,Ashfaq R,Shay JW,Euhus DM

更新日期：2006-09-01 00:00:00

abstract：:The clinical and pathological heterogeneity of breast cancer has instigated efforts to stratify breast cancer sub-types according to molecular profiles. These profiling efforts are now being augmented by large-scale functional screening of breast tumour cell lines, using approaches such as RNA interference. We have de...

journal_title：Breast cancer research and treatment

authors： Sims D,Bursteinas B,Gao Q,Jain E,MacKay A,Mitsopoulos C,Zvelebil M

更新日期：2010-11-01 00:00:00

abstract：:Our aim was to develop an accurate diagnostic system using gene expression analysis by means of DNA microarray for prognosis of node-negative and estrogen receptor (ER)-positive breast cancer patients in order to identify a subset of patients who can be safely spared adjuvant chemotherapy. A diagnostic system comprisi...

journal_title：Breast cancer research and treatment

authors： Naoi Y,Kishi K,Tanei T,Tsunashima R,Tominaga N,Baba Y,Kim SJ,Taguchi T,Tamaki Y,Noguchi S

更新日期：2011-08-01 00:00:00